進行期腎癌および肺転移を有する患者に対する養子免疫療法、アルデスロイキン、およびゾレドロン酸の併用療法

基本情報

NCT ID

NCT00588913

ステータス

完了

試験のフェーズ

第1/第2相

試験タイプ

介入

目標被験者数

20

治験依頼者名

National Cancer Institute (NCI)

概要

RATIONALE: Cellular adoptive immunotherapy uses a person's white blood cells that are treated in the laboratory to stimulate the immune system in different ways and stop tumor cells from growing. Aldesleukin may help the laboratory-treated white blood cells stay in the body longer. Drugs used in chemotherapy, such as zoledronic acid, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving cellular adoptive immunotherapy together with interleukin-2 and zoledronic acid may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects of giving cellular adoptive immunotherapy together with aldesleukin and zoledronic acid and to see how well it works in treating patients with stage IV kidney cancer and lung metastases.

対象疾患

介入

依頼者（Sponsor）

実施施設 (2)